BPS Offers a Unique IL-17A:IL-17RA Inhibitor Screening Assay Kit and Screening/Profiling Services

Share Article

BPS Bioscience, Inc. (“BPS”) announces the addition of a one-of-a-kind assay kit designed to screen for inhibitors of IL-17A interaction with IL-17RA.

IL-17A, also known as CTLA8, is a pro-inflammatory cytokine that plays a key role in mediating inflammation, autoimmunity, and host defense. It is mainly secreted by a subset of T helper cells known as TH17 cells. IL-17A can bind to IL-17 receptor A (IL-17RA) expressed on the surface of several target cells, such as synoviocytes and other mesenchymal cells where it stimulates production of pro-inflammatory cytokines like IL-6 and IL-8.

The first therapeutic antibody that inhibits IL-17A signaling was approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of psoriasis in 2015. Other biologics targeting this pathway are currently under development and, given the central role that IL-17 plays in mediating inflammatory responses, it is likely that more approvals will be won in the coming years for other indications such as psoriatic and rheumatoid arthritis, Crohn’s disease, multiple sclerosis, and ankylosing spondylitis.

BPS Bioscience’s IL-17RA:IL-17A Inhibitor Screening Assay Kit is designed for screening inhibitors of IL-17A:IL-17RA interaction. The kit comes in a simple-to-use, 96-well format and takes advantage of biotin-labeled IL-17RA to detect protein-protein interaction via Streptavidin-HRP and chemiluminescent detection. It provides researchers with a useful tool for screening of small molecules or antibodies to block IL17A:IL17RA interactions. In addition to the IL-17A:IL-17RA binding kit, BPS is also excited to offer IL-17 screening services, the only company to offer screening services of this kind.

“BPS is continually striving to offer researchers novel and unique products and services for drug discovery research,” said Henry Zhu, President and CEO, BPS Biosciences, Inc. "In 2016, we will continue to focus on developing innovative tools to screen for modulators of immune system function as the drug market is rapidly expanding in this area.”

To learn more about BPS Bioscience’s IL-17 assay kit, and IL-17 screening services, please visit http://bpsbioscience.com

About BPS Bioscience, Inc.
Headquartered in San Diego, California, BPS Bioscience, Inc. is a leading manufacturer of products for Immunotherapy research, as well as Acetyltransferases, Bromodomains, Cytokines, HDACs, Histone Demethylases, Immune checkpoint proteins, Kinases, Methyltransferases, Phosphatases, Phosphodiesterases, Poly ADP Ribose Polymerases (PARPs), Proteases, Ubiquitin Enzymes, and other Metabolic Enzymes. BPS offers one of the largest selections of recombinant enzymes and assay kits for drug discovery and continues to expand its portfolio of innovative drug discovery products. BPS also provides custom protein expression, biochemical and cell-based assays, and compound screening and profiling services. BPS has provided products and services to pharmaceutical companies and academic institutes in over 45 countries worldwide. By being at the forefront of technology development, BPS focuses on providing quality life science products and services in a timely manner that will help our customers to accelerate drug discovery and development for treatment of human diseases. Visit BPS’s website for more information: http://www.bpsbioscience.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Henry Zhu
BPS Bioscience
+1 (858) 829-3082
Email >

Scott VanderWel
BPS Bioscience
(858) 202-1401 122
Email >
Visit website